Puma Biotechnology | PBYI - Equity Capital And Reserves


Puma Biotechnology reported $115.27M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
Exelixis USD 1.94B 225.57M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Glaxosmithkline GBP 22.06B 360M Dec/2025
Incyte USD 5.62B 455.37M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Takeda JPY 7.77T 129.5B Mar/2026
TG Therapeutics USD 583.13M 64.89M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026